DCM
IMVT icon

Dupont Capital Management’s Immunovant IMVT Stock Holding History

Dupont Capital Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-34,088
Closed -$133K – 1616
2022
Q2 		$133K Buy
34,088
+9,055
+36% +$39.1K 0.01% 1117
2022
Q1 		$138K Sell
25,033
-2,214
-8% -$13.8K 0.01% 1200
2021
Q4 		$232K Buy
+27,247
New +$225K 0.01% 1074

Other funds holding IMVT

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dupont Capital Management's IMVT Position: Q3 2022 in Review

Dupont Capital Management sold out of Immunovant (IMVT) in Q3 2022, closing a stake of 34,088 shares — an estimated $133K sold.

Dupont Capital Management first reported a position in IMVT in Q4 2021 and held it in 3 quarters. The position peaked at $232K in Q4 2021. 112 funds tracked by Wall St. Rank hold IMVT as of Q3 2022.

  • Dupont Capital Management reported no remaining Immunovant position as of Q3 2022 after selling out during the quarter.
  • Dupont Capital Management sold 34,088 Immunovant shares in Q3 2022, an estimated $133K.
  • Dupont Capital Management first reported a position in Immunovant in Q4 2021 and held it in 3 quarters.
  • Dupont Capital Management's Immunovant position peaked at $232K in Q4 2021.
  • 112 funds tracked by Wall St. Rank held Immunovant as of Q3 2022.

Based on Dupont Capital Management's 13F filing for Q3 2022, filed 31 Oct 2022.